Overcoming Cancers Resistant to HER-2 Antibodies

1. General Introduction of Cancers responding to FDA-approved anti-HER2 antibodies (Trastuzumab)1B. Antibody Induction of Anticancer Immunity
2. Sensitization of Trastuzumab Response by the Combination with Pentuzumab
3. Sensitization by Lapatinib of Trastuzumab Resistance
4. Sensitization by Ganetespib (HSP90 inhibitor) of Trastuzumab Resistance
5. Sensitization by Paclitaxel of Trastuzumab Resistance
6. Sensitization by Celecoxib of Trastuzumab Resistance
7. Sensitization by Emantasine (T-DM1) of Trastuzumab Resistance
8. Sensitization by Anti-apoptotic Inhibitors of Trastuzumab Resistance
9. Sensitization by Kinase Inhibitors of Trastuzumab Resistance
10. Sensitization by Vinorelbine of Trastuzumab Resistance
11. Sensitization by Fulvestrant of Trastuzumab Resistance
12. Sensitization by IFF-1 Inhibitors of Trastuzumab Resistance
13. Sensitization by Liposomal Doxorubicin of Trastuzumab Resistance
14. Sensitization by Combination of Immunotherapy and Trastuzumab
15. Sensitization by Radiotherapy of Trastuzumab Resistance
16. Sensitization by Chemotherapy of Trastuzumab Resistance
17. New Development of Targeted Anti-HER-2 Antibodies

Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.

• Oncologia
• Gestão da industria biotecnologica
• Saude pessoal e pública

cancer; sensitizing agents; antibody therapy; Trastuzumab; anticancer immunity; Lapatinib; Ganetespib; Paclitaxel; Celecoxib; Emantasine; Anti-apoptotic Inhibitors; Kinase Inhibitors; Vinorelbine; Fulvestrant; IFF-1 Inhibitors; Liposomal Doxorubicin; immunotherapy; radiotherapy; chemotherapy